Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Catheter Ablation | 8 | 2023 | 113 | 1.690 |
Why?
|
| Atrial Fibrillation | 14 | 2020 | 410 | 1.550 |
Why?
|
| Atrial Flutter | 3 | 2023 | 20 | 1.010 |
Why?
|
| Cardiac Tamponade | 1 | 2023 | 10 | 0.810 |
Why?
|
| Defibrillators, Implantable | 4 | 2015 | 44 | 0.680 |
Why?
|
| Equipment Failure | 2 | 2014 | 25 | 0.490 |
Why?
|
| Electrodes, Implanted | 2 | 2013 | 54 | 0.480 |
Why?
|
| Postoperative Complications | 4 | 2017 | 823 | 0.460 |
Why?
|
| Thrombosis | 2 | 2017 | 78 | 0.410 |
Why?
|
| Atrial Function, Left | 2 | 2017 | 22 | 0.370 |
Why?
|
| Electrocardiography | 7 | 2023 | 623 | 0.360 |
Why?
|
| Heart Diseases | 1 | 2013 | 114 | 0.360 |
Why?
|
| Hypertension, Pulmonary | 1 | 2011 | 22 | 0.340 |
Why?
|
| Thoracoscopy | 3 | 2017 | 11 | 0.330 |
Why?
|
| Atrial Appendage | 2 | 2017 | 24 | 0.260 |
Why?
|
| Male | 19 | 2023 | 19441 | 0.240 |
Why?
|
| Humans | 22 | 2023 | 32282 | 0.240 |
Why?
|
| Risk Factors | 10 | 2020 | 3934 | 0.230 |
Why?
|
| Long QT Syndrome | 2 | 2020 | 44 | 0.210 |
Why?
|
| Positive-Pressure Respiration | 1 | 2023 | 14 | 0.210 |
Why?
|
| Device Removal | 2 | 2014 | 39 | 0.200 |
Why?
|
| Prospective Studies | 4 | 2023 | 2316 | 0.200 |
Why?
|
| Heart Conduction System | 2 | 2017 | 76 | 0.190 |
Why?
|
| Aged | 11 | 2023 | 10263 | 0.190 |
Why?
|
| Hemodynamics | 1 | 2023 | 164 | 0.190 |
Why?
|
| Artifacts | 1 | 2023 | 45 | 0.190 |
Why?
|
| Female | 17 | 2021 | 19945 | 0.180 |
Why?
|
| Postural Orthostatic Tachycardia Syndrome | 1 | 2021 | 9 | 0.170 |
Why?
|
| Aged, 80 and over | 4 | 2023 | 3900 | 0.170 |
Why?
|
| Treatment Outcome | 11 | 2017 | 3416 | 0.170 |
Why?
|
| Heart Atria | 1 | 2020 | 81 | 0.150 |
Why?
|
| Middle Aged | 12 | 2020 | 11851 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 100 | 0.150 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 773 | 0.150 |
Why?
|
| Retrospective Studies | 8 | 2020 | 3626 | 0.130 |
Why?
|
| Tennessee | 5 | 2016 | 98 | 0.130 |
Why?
|
| Intracranial Embolism | 1 | 2017 | 15 | 0.130 |
Why?
|
| Postoperative Period | 1 | 2017 | 95 | 0.130 |
Why?
|
| Brugada Syndrome | 1 | 2016 | 18 | 0.120 |
Why?
|
| Coronary Artery Bypass | 1 | 2017 | 100 | 0.120 |
Why?
|
| Drug Implants | 1 | 2015 | 10 | 0.120 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2016 | 122 | 0.120 |
Why?
|
| Prosthesis-Related Infections | 1 | 2015 | 31 | 0.110 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2015 | 5 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2015 | 10 | 0.110 |
Why?
|
| Pacemaker, Artificial | 1 | 2015 | 40 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2017 | 77 | 0.110 |
Why?
|
| Angioplasty, Laser | 1 | 2014 | 1 | 0.100 |
Why?
|
| Thoracotomy | 1 | 2014 | 19 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2017 | 1425 | 0.100 |
Why?
|
| Action Potentials | 2 | 2017 | 212 | 0.100 |
Why?
|
| beta-Alanine | 1 | 2013 | 2 | 0.100 |
Why?
|
| Embolism | 1 | 2013 | 7 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2013 | 31 | 0.100 |
Why?
|
| Heart Ventricles | 2 | 2016 | 146 | 0.100 |
Why?
|
| Warfarin | 1 | 2013 | 32 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 324 | 0.100 |
Why?
|
| Incidence | 4 | 2020 | 1241 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 1437 | 0.090 |
Why?
|
| Obesity, Morbid | 1 | 2012 | 72 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 1050 | 0.080 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2010 | 5 | 0.080 |
Why?
|
| Tissue Adhesives | 1 | 2010 | 6 | 0.080 |
Why?
|
| Triamcinolone | 1 | 2010 | 12 | 0.080 |
Why?
|
| Anesthesia | 1 | 2010 | 63 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2010 | 146 | 0.070 |
Why?
|
| Pressoreceptors | 1 | 2009 | 7 | 0.070 |
Why?
|
| Ventricular Function | 1 | 2009 | 8 | 0.070 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2009 | 13 | 0.070 |
Why?
|
| Survival Rate | 3 | 2017 | 893 | 0.070 |
Why?
|
| Myocardial Contraction | 1 | 2009 | 59 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2017 | 1840 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 821 | 0.070 |
Why?
|
| Endocardium | 2 | 2021 | 5 | 0.070 |
Why?
|
| Stroke | 1 | 2013 | 691 | 0.060 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2017 | 58 | 0.060 |
Why?
|
| Heart Rate | 2 | 2020 | 362 | 0.060 |
Why?
|
| Comorbidity | 2 | 2020 | 565 | 0.060 |
Why?
|
| Quinidine | 1 | 2005 | 2 | 0.060 |
Why?
|
| Confidence Intervals | 2 | 2017 | 141 | 0.060 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2005 | 17 | 0.060 |
Why?
|
| Recurrence | 2 | 2016 | 285 | 0.050 |
Why?
|
| Time Factors | 3 | 2017 | 2205 | 0.050 |
Why?
|
| Angina Pectoris | 1 | 2023 | 20 | 0.050 |
Why?
|
| Oxazines | 1 | 2003 | 2 | 0.050 |
Why?
|
| Neocortex | 1 | 2003 | 4 | 0.050 |
Why?
|
| Dioxoles | 1 | 2003 | 4 | 0.050 |
Why?
|
| Prevalence | 2 | 2016 | 955 | 0.050 |
Why?
|
| Receptors, AMPA | 1 | 2003 | 16 | 0.050 |
Why?
|
| Methamphetamine | 1 | 2003 | 20 | 0.050 |
Why?
|
| Rotation | 1 | 2003 | 51 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2015 | 456 | 0.050 |
Why?
|
| Central Nervous System Stimulants | 1 | 2003 | 82 | 0.040 |
Why?
|
| Piperidines | 1 | 2003 | 137 | 0.040 |
Why?
|
| Sinoatrial Node | 1 | 2021 | 4 | 0.040 |
Why?
|
| Tachycardia, Sinus | 1 | 2021 | 5 | 0.040 |
Why?
|
| Chest Pain | 1 | 2023 | 205 | 0.040 |
Why?
|
| Pericardium | 2 | 2010 | 52 | 0.040 |
Why?
|
| Dogs | 2 | 2010 | 126 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2020 | 484 | 0.030 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2017 | 5 | 0.030 |
Why?
|
| Surgical Instruments | 1 | 2017 | 25 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 178 | 0.030 |
Why?
|
| Organ Size | 1 | 2016 | 221 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 368 | 0.030 |
Why?
|
| Independent Living | 1 | 2016 | 90 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2020 | 861 | 0.030 |
Why?
|
| Causality | 1 | 2015 | 37 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2015 | 33 | 0.030 |
Why?
|
| Absorbable Implants | 1 | 2015 | 24 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 324 | 0.030 |
Why?
|
| Germany | 1 | 2015 | 6 | 0.030 |
Why?
|
| Boston | 1 | 2015 | 16 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 174 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2015 | 14 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2015 | 37 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 211 | 0.030 |
Why?
|
| Reoperation | 1 | 2016 | 252 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 146 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 757 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 287 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 413 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 555 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 883 | 0.030 |
Why?
|
| Endocarditis | 1 | 2013 | 22 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 651 | 0.020 |
Why?
|
| Premedication | 1 | 2013 | 15 | 0.020 |
Why?
|
| Phenotype | 1 | 2015 | 622 | 0.020 |
Why?
|
| European Continental Ancestry Group | 1 | 2016 | 1076 | 0.020 |
Why?
|
| Mortality | 1 | 2013 | 122 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2013 | 122 | 0.020 |
Why?
|
| Animals | 3 | 2010 | 8199 | 0.020 |
Why?
|
| Adult | 2 | 2014 | 9259 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 655 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 101 | 0.020 |
Why?
|
| African Americans | 1 | 2016 | 1335 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2012 | 863 | 0.020 |
Why?
|
| United States | 1 | 2016 | 4072 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 2240 | 0.020 |
Why?
|
| Memory | 1 | 2009 | 202 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 1083 | 0.020 |
Why?
|
| Adrenergic Agents | 1 | 2003 | 7 | 0.010 |
Why?
|
| Stereotyped Behavior | 1 | 2003 | 14 | 0.010 |
Why?
|
| Oxidopamine | 1 | 2003 | 24 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2003 | 13 | 0.010 |
Why?
|
| Substantia Nigra | 1 | 2003 | 20 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 40 | 0.010 |
Why?
|
| Autoradiography | 1 | 2003 | 51 | 0.010 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2003 | 27 | 0.010 |
Why?
|
| Cell Count | 1 | 2003 | 51 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2003 | 86 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2003 | 62 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2003 | 143 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 545 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2003 | 299 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 717 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2003 | 897 | 0.010 |
Why?
|
| Rats | 1 | 2003 | 1895 | 0.010 |
Why?
|